Skip to main content

Advertisement

SpringerLink
Log in

Emergency reversal of antithrombotic treatment

  • EM - Review
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet strategies can be corrected by the administration of platelet concentrate or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors has been introduced and most of these agents are presently being evaluated in clinical studies. The new generation anticoagulants include specific inhibitors of factor IIa, factor Xa (including pentasaccharides) and agents that interfere with tissue factor activity. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ (2008) Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:110S–112S

    Article  PubMed  Google Scholar 

  2. Mannucci PM, Levi M (2007) Prevention and treatment of major blood loss. N Engl J Med 356:2301–2311

    Article  PubMed  CAS  Google Scholar 

  3. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:257S–298S

    Article  PubMed  CAS  Google Scholar 

  4. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782

    Article  PubMed  Google Scholar 

  5. Algra A (2007) Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 6:115–124

    Article  PubMed  CAS  Google Scholar 

  6. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:141S–159S

    Article  PubMed  CAS  Google Scholar 

  7. Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM Jr, Stanley JC (1987) Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 48:31–40

    Article  PubMed  CAS  Google Scholar 

  8. Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M (1986) Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 16:139–146

    PubMed  CAS  Google Scholar 

  9. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR (1990) Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 63:271–274

    PubMed  Google Scholar 

  10. Bang CJ, Berstad A, Talstad I (1991) Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 21:155–160

    PubMed  CAS  Google Scholar 

  11. Caplan SN, Berkman EM (1976) Letter: protamine sulfate and fish allergy. N Engl J Med 295:172

    PubMed  CAS  Google Scholar 

  12. Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN (1997) Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 13:394–397

    Article  PubMed  CAS  Google Scholar 

  13. Mauney MC, Buchanan SA, Lawrence WA, Bishop A, Sinclair K, Daniel TM, Tribble CG, Kron IL (1995) Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg 22:264–269

    Article  PubMed  CAS  Google Scholar 

  14. Dellagrammaticas D, Lewis SC, Gough MJ (2008) Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg 36:41–44

    Article  PubMed  CAS  Google Scholar 

  15. D’Ambra M (1996) Restoration of the normal coagulation process: advances in therapies to antagonize heparin. J Cardiovasc Pharmacol 27 (suppl 1):S58–S62

    Google Scholar 

  16. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Zimmermann JJ, Lappas DG (1994) In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 79:670–674

    Article  PubMed  CAS  Google Scholar 

  17. Tao W, Deyo DJ, Brunston RL Jr, Vertrees RA, Zwischenberger JB (1998) Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device—an alternative to protamine. Crit Care Med 26:1096–1102

    Article  PubMed  CAS  Google Scholar 

  18. Buller HR (2002) Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost 28(suppl 2):41–48

    Article  PubMed  Google Scholar 

  19. Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879

    Article  PubMed  CAS  Google Scholar 

  20. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550–2554

    Article  PubMed  CAS  Google Scholar 

  21. Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M (2004) Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 124:653–658

    Article  PubMed  CAS  Google Scholar 

  22. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:160S–198S

    Article  PubMed  CAS  Google Scholar 

  23. Dentali F, Ageno W, Crowther M (2006) Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 4:1853–1863

    Article  PubMed  CAS  Google Scholar 

  24. Baglin T (1998) Management of warfarin (coumarin) overdose. Blood Rev 12:91–98

    Article  PubMed  CAS  Google Scholar 

  25. Whitling AM, Bussey HI, Lyons RM (1998) Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 158:2136–2140

    Article  PubMed  CAS  Google Scholar 

  26. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE (2001) A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 115:145–149

    Article  PubMed  CAS  Google Scholar 

  27. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W (2002) Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 137:251–254

    PubMed  CAS  Google Scholar 

  28. Weibert RT, Le DT, Kayser SR, Rapaport SI (1997) Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 126:959–962

    PubMed  CAS  Google Scholar 

  29. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC (1999) Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 83:286–287

    Article  PubMed  CAS  Google Scholar 

  30. Raj G, Kumar R, McKinney WP (1999) Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 159:2721–2724

    Article  PubMed  CAS  Google Scholar 

  31. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D (2003) Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 163:2469–2473

    Article  PubMed  CAS  Google Scholar 

  32. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O’malley PG (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 166:391–397

    Article  PubMed  CAS  Google Scholar 

  33. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, de Vries-Goldschmeding HJ, Rakers E, Levi M (2007) Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon. Thromb Haemost 98:747–755

    PubMed  Google Scholar 

  34. Martin JC (1991) Anaphylactoid reactions and vitamin K. Med J Aust 155:851

    PubMed  CAS  Google Scholar 

  35. Fiore LD, Scola MA, Cantillon CE, Brophy MT (2001) Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 11:175–183

    Article  PubMed  CAS  Google Scholar 

  36. Dentali F, Ageno W (2004) Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica 89:857–862

    PubMed  CAS  Google Scholar 

  37. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M (2007) Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82:82–92

    Article  PubMed  CAS  Google Scholar 

  38. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF (1997) Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77:477–480

    PubMed  CAS  Google Scholar 

  39. Yasaka M, Sakata T, Naritomi H, Minematsu K (2005) Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 115:455–459

    Article  PubMed  CAS  Google Scholar 

  40. Junagade P, Grace R, Gover P (2007) Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology 12:439–440

    Article  PubMed  CAS  Google Scholar 

  41. van AL, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF (2006) Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118:313–320

  42. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM (2006) Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4:967–970

    Article  PubMed  CAS  Google Scholar 

  43. Kessler CM (2006) Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost 4:963–966

    Article  PubMed  CAS  Google Scholar 

  44. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H (2008) Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6:622–631

    Article  PubMed  CAS  Google Scholar 

  45. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B (2008) Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 83:137–143

    Article  PubMed  CAS  Google Scholar 

  46. Levi M (2007) Disseminated intravascular coagulation. Crit Care Med 35:2191–2195

    Article  PubMed  CAS  Google Scholar 

  47. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U (1998) The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 9:741–748

    Article  PubMed  CAS  Google Scholar 

  48. Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE (2006) Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26:1091–1098

    Article  PubMed  CAS  Google Scholar 

  49. Deveras RA, Kessler CM (2002) Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884–888

    PubMed  CAS  Google Scholar 

  50. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J (2003) Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 14:469–477

    Article  PubMed  CAS  Google Scholar 

  51. Levi M (2005) New antithrombotics in the treatment of thromboembolic disease. Eur J Intern Med 16:230–237

    Article  PubMed  CAS  Google Scholar 

  52. Strebel N, Prins M, Agnelli G, Buller HR (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162:1451–1456

    Article  PubMed  CAS  Google Scholar 

  53. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG (2002) Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors. Cardiovasc Drug Rev 20:37–52

    PubMed  CAS  Google Scholar 

  54. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G (2001) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 161:2215–2221

    Article  PubMed  CAS  Google Scholar 

  55. Weitz JI, Buller HR (2002) Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105:1004–1011

    Article  PubMed  CAS  Google Scholar 

  56. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H (2002) Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107:93–99

    Article  PubMed  CAS  Google Scholar 

  57. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956

    Article  PubMed  CAS  Google Scholar 

  58. Woltz M, Levi M, Sarich TC, Bostrom SL, Ericksson UG, Erikkson M, Svensson M, Weitz JI, Elg M, Wahlander K (2004) Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb Haemost 91(6):1090–1096

    Google Scholar 

  59. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180–187

    Article  PubMed  CAS  Google Scholar 

  60. Shantsila E, Lip GY (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 9:1020–1033

    PubMed  CAS  Google Scholar 

  61. Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP (1996) Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 93:2149–2154

    Article  PubMed  CAS  Google Scholar 

  62. Moons AH, Peters RJ, Bijsterveld NR, Piek JJ, Prins MH, Vlasuk GP, Rote WE, Buller HR (2003) Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 41:2147–2153

    Article  PubMed  CAS  Google Scholar 

  63. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van der MJ, Piovella F, Raskob G, Gent M (2001) Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104:74–78

  64. Allen GA, Hoffman M, Roberts HR, Monroe DM III (2002) Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 49:S7–S14

    PubMed  Google Scholar 

  65. Hedner U, Erhardtsen E (2002) Potential role for rFVIIa in transfusion medicine. Transfusion 42:114–124

    Article  PubMed  CAS  Google Scholar 

  66. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR (2001) Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103:2555–2559

    PubMed  CAS  Google Scholar 

  67. Patrono C, Baigent C, Hirsh J, Roth G (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:199S–233S

    Article  PubMed  CAS  Google Scholar 

  68. Merritt JC, Bhatt DL (2004) The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 17:21–27

    Article  PubMed  CAS  Google Scholar 

  69. Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45:456–459

    Article  PubMed  CAS  Google Scholar 

  70. Richardson DW, Robinson AG (1985) Desmopressin. Ann Intern Med 103:228–239

    PubMed  CAS  Google Scholar 

  71. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B (2003) Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 102:4594–4599

    Article  PubMed  CAS  Google Scholar 

  72. Anonymous (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee (see comments). Lancet 348:1329–1339

  73. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  PubMed  CAS  Google Scholar 

  74. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv 69:334–340

    Article  PubMed  Google Scholar 

  75. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ (2007) Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 5:82–90

    Article  PubMed  CAS  Google Scholar 

  76. Leithauser B, Zielske D, Seyfert UT, Jung F (2008) Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 39:293–302

    PubMed  CAS  Google Scholar 

  77. Reiter R, Jilma-Stohlawetz P, Horvath M, Jilma B (2005) Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion 45:420–426

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

The author declares that he has no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine (F-4), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marcel Levi

Authors
  1. Marcel Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel Levi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levi, M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 4, 137–145 (2009). https://doi.org/10.1007/s11739-008-0201-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-008-0201-8

Keywords

Search

Navigation